癌症绝症患者的萨尔科佩尼亚:临床影响,诊断挑战和管理策略
Se-Il Go1, Myoung Hee Kang1, Hoon-Gu Kim1
1Division of Hematology-Oncology, Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Korea.
Journal of hospice and palliative care
|March 12, 2025
概括
肉,肌肉质量和力量的损失,常见于绝症癌症患者,但在息治疗中经常错过. 管理侧重于舒适性和功能,而不是肌肉增长.
科学领域:
- 老年学是一门学科.
- 在瘤学瘤学.
- 抚慰性护理是一种缓解性护理.
背景情况:
- 骨肌肉质量和力量的渐进性损失萨尔科佩尼亚,在绝症癌症患者中很常见.
- 它显著影响功能状态,症状负担和生活质量.
- 在息护理机构中, Sarcopenia 经常被忽视.
研究的目的:
- 突出挑战,并提出可行的方法来诊断末期癌症患者的sarcopenia.
- 在息护理的背景下,概述萨科佩尼亚的适当管理策略.
- 为了指导未来的研究方向,在终身癌症护理中对萨尔科佩尼亚进行研究.
主要方法:
- 讨论了在这个人群中对萨科佩尼亚的常规诊断成像的局限性.
- 突出了其他评估工具:力量,帮助行走,从椅子上起身,爬楼梯和落问卷 (SARC-F),人体测量和生物电阻分析.
- 审查当前和研究中的管理方法,包括营养支持,运动和药物治疗.
主要成果:
- 在绝症癌症患者中存在可行的成像诊断替代方案,用于治疗癌症患者的肉症.
- 管理应该优先考虑缓解症状,功能维护和患者舒适度,而不是恢复肌肉质量.
- 营养和运动干预措施需要仔细考虑预后和患者的目标; 积极的治疗通常不建议.
结论:
- 在绝症癌症患者中, Sarcopenia 的评估和管理需要在息治疗中采取量身定制的,以患者为中心的方法.
- 需要进一步的研究来完善评估工具,并制定符合息治疗原则的干预措施.
- 专注于生活质量和个性化需求对于解决生命末期的肉症至关重要.
相关概念视频
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:21Barrett Esophagus-II: Clinical Manifestations and Management
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure entails...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:29Cardiomyopathy VI: Nursing Management
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...